For instance, the MEDIOLA study [105], a phase II trial, evaluated the combination of the PARP inhibitor olaparib and the PD‐L1 inhibitor durvalumab in patients with platinum‐sensitive recurrent ovarian cancer. Here, PARP1 is linked to ovarian carcinoma.